B3-fail date is december 2023.D6a-implant date is (b)(6) 2023.A review of the device labeling was completed.Iritis and iop elevation from baseline are identified in the labeling as known adverse events following icl implantation.The directions for use (dfu) states for complications and adverse reactions adverse reactions and complications due to, or following surgery and implantation of any evo/evo+ ticl may include, but are not limited to: uveitis/iritis, an iop elevation from baseline.The dfu states a caution: staar surgical evo|evo+ticl and disposable accessories are packaged and sterilized for single use only.Cleaning, refurbishing and/or resterilization are not applicable to these devices.If one of these devices were reused after cleaning, refurbishing, it is highly probable that it would be contaminated and the contamination could result in infection and/or inflammation.Iritis is an inflammatory condition which is common after intra-ocular surgery, however this is usually mild and does not require any additional interventions beyond the standard post-op regimen.In some cases the degree of inflammation may be more severe.Procedural factors including surgical technique, inadvertent intra-operative trauma and the use of pro-inflammatory substances into the eye may have contributed to the event.An exact cause could not be determined as the event could be multifactorial in nature including patient and/or procedure related factors.Claim# (b)(4).
|